Navigation Links
Chiltern Announces Additional Investment in Endpoint
Date:6/16/2011

LONDON, June 16, 2011 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO) announced an additional financial investment in Endpoint Clinical, Inc. (endpoint) further strengthening their strategic partnership with the company established in April 2009.

Glenn Kerkhof, Chiltern CEO, stated, "Chiltern's decision to increase our investment in endpoint reflects our aligned vision for the future of endpoint's PULSE platform, enabling endpoint to provide an unparalleled combination of premium client service and advanced technology solutions. Jon Dole and Tom O'Connell of endpoint have brought a new level of energy and innovation to Interactive Response Technology (IRT). Since our partnership began over a year ago, endpoint has delivered high quality, cost effective services to clients with both accuracy and speed. endpoint is successfully responding with best- in-class IVR/IWR solutions and as a result exceeding client expectations."

Jonathan Dole, endpoint CEO, stated, "Chiltern has been an excellent partner for us over the past year, and we couldn't be more pleased with their continued support in our vision for IRT. Chiltern's global footprint and their overall support of our growing business have proven invaluable in moving us forward. Chiltern's enthusiasm and investment affirms our confidence in the solutions we are bringing to the marketplace. With PULSE we are delighting our clients with our fresh and logical approach to systems development, giving our customers the agility they need in a constantly changing R&D environment."

PULSE is endpoint's fully configurable system which allows users to design and deploy clinical trial IRT systems at a fraction of the time and cost of other providers, was launched in January 2010. Providing both high speed of deployment and flawless quality, PULSE simultaneously designs systems that can be accessed via the phone, web, or mobile device.  

Company profilesChiltern:Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs around 1,300 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. www.chiltern.com.

endpoint: endpoint is an innovative company dedicated to the development of the leading Interactive Response Technology (IVR/IWR) platforms for the life sciences industry. endpoint's founding team members have been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma and biotech companies for domestic and global  studies with experience across a broad range of therapeutic areas and global implementations. www.endpointclinical.com Contact:Natalie Chong

Susan OjanenMarketing Director

Marketing ExecutiveChiltern International Ltd.

Chiltern International Inc.UK

USATel: +44 (0) 1753 512 000

Tel: +1 (423) 968 9533natalie.chong@chiltern.com

susan.ojanen@chiltern.comRich Mullikin, APRMarketing DirectorendpointUSATel: +1 (925) 779 9115Email: rmullikin@endpointclinical.com
'/>"/>

SOURCE Chiltern
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chiltern Early Phase: Fully Integrated and Business Ready
2. Chiltern Is a Nominee on the SCRIP CRO of the Year Award Shortlist
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... ... Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against ... previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
(Date:1/11/2017)... ... 11, 2017 , ... Symbios Technologies, Inc., a ... Science Foundation (NSF) has awarded Symbios a Small Business Innovation Research (SBIR) ... the Symbios Tubular Plasma Reactor™ (TPR™) by scaling the system for first customer ...
(Date:1/11/2017)... 11, 2017  GenVec, Inc. (NASDAQ: ... today that its chief scientific officer, Douglas ...  "AdenoVerse™ platform for translational development of innovative gene ... the upcoming Phacilitate Cell & Gene Therapy World ... Florida.  Dr. Brough,s presentation will highlight the utility ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):